11 research outputs found
Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier
Brain edema is an important factor leading to morbidity and mortality associated with primary brain tumors. Dexamethasone, a synthetic glucocorticoid, is routinely prescribed with antineoplastic agents to alleviate pain associated with chemotherapy and reduce intracranial pressure. We investigated whether dexamethasone treatment increased the expression and activity of multidrug resistance (MDR) transporters at the blood-brain barrier. Treatment of primary rat brain microvascular endothelial cells with submicromolar concentrations of dexamethasone induced significantly higher levels of drug efflux transporters such as breast cancer resistance protein (abcg2), P-glycoprotein (P-gp; abcb1a/abcb1b), and MDR protein 2 (Mrp2; abcc2) as indicted by protein and mRNA levels as well as by functional activity. The effect of dexamethasone on transporter function was significant within 6 h of treatment, was dose dependent, and was reversible. Dexamethasone-induced upregulation of Bcrp and P-gp expression and function was partially abrogated by the glucocorticoid receptor (GR) antagonist RU486. In contrast, RU486 had no effect on the dexamethasone-induced upregulation of Mrp2, suggesting a GR-independent regulation of Mrp2, and a GR-dependent regulation of P-gp and Bcrp. In addition to the dexamethasone-induced upregulation of MDR transporters, we measured a dose-dependent and reversible increase in the expression of the nuclear transcription factor pregnane xenobiotic receptor (PXR). Administering dexamethasone to rats caused increased expression of PXR in brain microvessels within 24 h. These results suggest that adjuvant therapy with corticosteroids such as dexamethasone in the treatment of brain tumors may increase the expression of MDR transporters at the blood-brain barrier through pathways involving GR and PXR
Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography–electrospray ionization-tandem mass spectrometry (LC–ESI-MS/MS)
Developmental pharmacokinetics of topotecan (TPT), a renally excreted drug, in infants and young children with brain tumors.
Magnetic Resonance Imaging–Guided Microdialysis Cannula Implantation in a Spontaneous High-Grade Glioma Murine Model
Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral AdministrationS⃞
Nutlin-3a is an MDM2 inhibitor that is under investigation in preclinical models for
a variety of pediatric malignancies, including retinoblastoma, rhabdomyosarcoma,
neuroblastoma, and leukemia. We used physiologically based pharmacokinetic (PBPK)
modeling to characterize the disposition of nutlin-3a in the mouse. Plasma protein
binding and blood partitioning were assessed by in vitro studies. After intravenous
(10 and 20 mg/kg) and oral (50, 100, and 200 mg/kg) dosing, tissue concentrations of
nutlin-3a were determined in plasma, liver, spleen, intestine, muscle, lung, adipose,
bone marrow, adrenal gland, brain, retina, and vitreous fluid. The PBPK model was
simultaneously fit to all pharmacokinetic data using NONMEM. Nutlin-3a exhibited
nonlinear binding to murine plasma proteins, with the unbound fraction ranging from
0.7 to 11.8%. Nutlin-3a disposition was characterized by rapid absorption with peak
plasma concentrations at approximately 2 h and biphasic elimination consistent with a
saturable clearance process. The final PBPK model successfully described the plasma
and tissue disposition of nutlin-3a. Simulations suggested high bioavailability,
rapid attainment of steady state, and little accumulation when administered once or
twice daily at dosages up to 400 mg/kg. The final model was used to perform
simulations of unbound tissue concentrations to determine which dosing regimens are
appropriate for preclinical models of several pediatric malignancies